22 results on '"Abdel-Rahman, Sultan"'
Search Results
2. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial
- Author
-
Issels, Rolf D., Boeck, Stefan, Pelzer, Uwe, Mansmann, Ulrich, Ghadjar, Pirus, Lindner, Lars H., Albertsmeier, Markus, Angele, Martin K., Schmidt, Michael, Xu, Yujun, Bahra, Marcus, Pratschke, Johann, Schoenberg, Michael, Thasler, Wolfgang E., Salat, Christoph, Stoetzer, Oliver J., Knoefel, Wolfram T., Graf, Dirk, Wessalowski, Rüdiger, Keitel-Anselmino, Verena, Koenigsrainer, Alfred, Bitzer, Michael, Zips, Daniel, Bamberg, Michael, Fietkau, Rainer, Ott, Oliver, Kawecki, Maciej, Wyrwicz, Lucjan, Rutkowski, Piotr, Rentsch, Markus, Ababei, Juliana, Reichardt, Peter, Rigamonti, Marco, Weber, Bernhard, Abdel-Rahman, Sultan, Tschoep–Lechner, Katharina, Jauch, Karl-Walter, Bruns, Christiane J., Oettle, Helmut, von Bergwelt-Baildon, Michael, Heinemann, Volker, and Werner, Jens
- Published
- 2023
- Full Text
- View/download PDF
3. Expanding Valve Repair in Rheumatic Heart Disease
- Author
-
Ahmed Afifi, Nairouz Shehata, Mohamed Nagi, Abdel Rahman Sultan, and Magdi Yacoub
- Subjects
rheumatic mitral repair ,rheumatic aortic repair ,rheumatic valve imaging ,rheumatic valve disease ,rheumatic valve surgery ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Rheumatic heart disease is a serious ailment with significant morbidity and mortality in endemic areas; yet, there is no agreement on indication, timing, and surgical modality for treating rheumatic valve affection. There is mounting evidence that rheumatic mitral valve repair is possible with good long-term results, less is the case with rheumatic aortic valve disease. We discuss the surgical approach for both valves emphasizing the role of multimodality imaging.
- Published
- 2022
- Full Text
- View/download PDF
4. Quality assurance guidelines for superficial hyperthermia clinical trials: II. Technical requirements for heating devices
- Author
-
Dobšíček Trefná, Hana, Crezee, Johannes, Schmidt, Manfred, Marder, Dietmar, Lamprecht, Ulf, Ehmann, Michael, Nadobny, Jacek, Hartmann, Josefin, Lomax, Nicolleta, Abdel-Rahman, Sultan, Curto, Sergio, Bakker, Akke, Hurwitz, Mark D., Diederich, Chris J., Stauffer, Paul R., and Van Rhoon, Gerard C.
- Published
- 2017
- Full Text
- View/download PDF
5. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
- Author
-
Issels, Rolf D, Lindner, Lars H, Verweij, Jaap, Wust, Peter, Reichardt, Peter, Schem, Baard-Christian, Abdel-Rahman, Sultan, Daugaard, Soeren, Salat, Christoph, Wendtner, Clemens-Martin, Vujaskovic, Zeljko, Wessalowski, Rüdiger, Jauch, Karl-Walter, Dürr, Hans Roland, Ploner, Ferdinand, Baur-Melnyk, Andrea, Mansmann, Ulrich, Hiddemann, Wolfgang, Blay, Jean-Yves, and Hohenberger, Peter
- Published
- 2010
- Full Text
- View/download PDF
6. Concomitant trimodality therapy of re-irradiation, chemotherapy and regional hyperthermia for a pretreated inoperable sarcoma recurrence
- Author
-
Li, Minglun, Andrä, Claudia, Niyazi, Maximilian, Issels, Rolf D., Abdel-Rahman, Sultan, Oskan, Feras, and Manapov, Farkhad
- Published
- 2015
- Full Text
- View/download PDF
7. Quality assurance for clinical studies in regional deep hyperthermia
- Author
-
Bruggmoser, Gregor, Bauchowitz, Stefan, Canters, Richard, Crezee, Hans, Ehmann, Michael, Gellermann, Johanna, Lamprecht, Ulf, Lomax, Nicoletta, Messmer, Marc Benjamin, Ott, Oliver, Abdel-Rahman, Sultan, Sauer, Rolf, Schmidt, Manfred, Thomsen, Andreas, Wessalowski, Rüdiger, and van Rhoon, Gerard
- Published
- 2011
- Full Text
- View/download PDF
8. Response to Neoadjuvant Chemotherapy Combined With Regional Hyperthermia Predicts Long-Term Survival for Adult Patients With Retroperitoneal and Visceral High-Risk Soft Tissue Sarcomas
- Author
-
Wendtner, Clemens-M., Abdel-Rahman, Sultan, Krych, Matthäus, Baumert, Jens, Lindner, Lars H., Baur, Andrea, Hiddemann, Wolfgang, and Issels, Rolf D.
- Published
- 2002
9. Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience.
- Author
-
Stoetzer, Oliver, Di Gioia, Dorit, Issels, Rolf Dieter, Abdel-Rahman, Sultan, Mansmann, Ulrich, Lindner, Lars Hartwin, Gluz, Oleg, Würstlein, Rachel, Braun, Michael, Hamann, Moritz, Edler von Koch, Franz, Harbeck, Nadia, and Salat, Christoph
- Subjects
BODY temperature ,ANTHRACYCLINES ,REGRESSION analysis ,HEALTH outcome assessment ,LYMPH nodes ,ANTIMETABOLITES ,COMBINED modality therapy ,POLYMERASE chain reaction ,BREAST tumors ,DOSE-response relationship in biochemistry - Abstract
Background: Patients with triple-negative primary breast cancer (TNBC) who have residual invasive carcinoma after neoadjuvant chemotherapy have poor prognosis. Proven adjuvant approaches to reduce the risk of recurrence and improve outcome in patients with non-pathological complete response (non-pCR) are limited. Methods: From our institutional registry, a consecutive case series of patients with operable, unilateral, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy underwent adjuvant treatment with gemcitabine plus cisplatin combined with regional hyperthermia. For quality assurance, we analyzed feasibility, efficacy, and toxicity of all treated patients. Outcome was evaluated for the entire group of patients as well as for the subgroups of patients with or without lymph node involvement at baseline (cN0/ cN+). Results: From August 2012 to January 2019, we offered this treatment to 53 patients at our center as part of routine care. The median follow-up was 38 months. The majority of patients (64.2%) had cT2 tumors at baseline. Twenty-four patients (45%) were clinically node positive as evaluated by sonography. Thirty-nine patients (74%) had grade 3, and 14 patients (26%) had grade 2 tumors. Forty-one patients (76%) showed a regression grade 1 according to Sinn. Patients received a median of six treatment cycles of gemcitabine and cisplatin (range 1–6) combined with 12 applications of regional hyperthermia (median 12, range 2–12). Disease-free survival (DFS) at 3 years was 57.5%. In patients with no lymph node involvement at baseline (cN0), DFS at 3 years was significantly higher than in initially node-positive (cN+) patients (80 vs. 31%; p = 0.001). Overall survival (OS) at 3 years was 81.6%. In patients with no lymph node involvement at baseline (cN0), OS at 3 years was significantly higher than in node-positive (cN+) patients (93 vs. 70.4%; p = 0.02). Overall, grade 3/4 toxicities were leukopenia (38%), thrombocytopenia (4%), and anemia (4%). Conclusion: After standard neoadjuvant chemotherapy containing anthracycline plus cyclophosphamide followed by taxanes, addition of adjuvant gemcitabine plus cisplatin in combination with regional hyperthermia was safe and effective in TNBC patients with non-pCR. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma.
- Author
-
Bücklein, Veit, Limmroth, Christina, Kampmann, Eric, Schuebbe, Gesa, Issels, Rolf, Roeder, Falk, Angele, Martin, Dürr, Hans Roland, Knösel, Thomas, Abdel-Rahman, Sultan, Di Gioia, Dorit, and Lindner, Lars H.
- Subjects
ANTHRACYCLINES ,COMBINED modality therapy ,ETOPOSIDE ,METASTASIS ,NEUTROPENIA ,SARCOMA ,SOFT tissue tumors ,SURVIVAL analysis (Biometry) ,THERMOTHERAPY ,TUMOR classification ,TREATMENT effectiveness ,DISEASE progression ,SALVAGE therapy ,CARBOPLATIN ,IFOSFAMIDE ,TUMOR grading ,DISEASE risk factors - Abstract
Patients with localized relapse of soft-tissue sarcoma (STS) after anthracycline-based chemotherapy have a dismal prognosis, particularly when surgery is not possible. To facilitate resection and improve long-term tumor control, we applied an intensified perioperative treatment consisting of ICE (ifosfamide 6 g/m
2 , carboplatin 400 mg/m2 , and etoposide 600 mg/m2 ) in combination with regional hyperthermia (RHT) to maximize local control. Here, we retrospectively evaluate the safety and efficacy of this strategy. Patients aged ≥18 years with locally advanced high-risk STS, either with or without metastasis, treated with ICE + RHT after the failure of first-line anthracycline-based chemotherapy were included in this analysis. Radiographic response, toxicity, progression-free survival (PFS), and overall survival (OS) were assessed. Between 1996 and 2018, 213 sarcoma patients received ICE at our centre. Of these, 110 patients met the selection criteria (progressive disease, suitable high-grade STS histology, anthracycline pretreatment, RHT treatment) for this analysis. Fifty-four patients had locally advanced disease without metastases (LA-STS), and 56 patients had additional metastatic disease (M-STS). Disease control was achieved in 59% of LA-STS patients and in 47% of M-STS patients. For LA-STS, 21% of the patients achieved radiographic response, facilitating resection in 4 patients (7%), compared with 11% of the M-STS patients, facilitating resection in 5 patients (9%). PFS was significantly longer in LA-STS than in M-STS (10 vs. 4 months, p < 0.0001). Median OS was 26 months in LA-STS and 12 months in M-STS. Disease control was the only independent prognostic factor for improved OS in multivariate analysis. Toxicity was high with neutropenic fever occurring in 25% of the patients and three therapy-related deaths (3%). ICE + RHT demonstrated activity in high-risk STS and facilitated resection in selected patients after anthracycline failure. Disease control was associated with improved OS. Based on the observed toxicities, the dose should be reduced to 75%. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
11. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
- Author
-
Issels, Rolf D., Lindner, Lars H., Verweij, Jaap, Wessalowski, Rüdiger, Reichardt, Peter, Wust, Peter, Ghadjar, Pirus, Hohenberger, Peter, Angele, Martin, Salat, Christoph, Vujaskovic, Zeljko, Daugaard, Soeren, Mella, Olav, Mansmann, Ulrich, Dürr, Hans Roland, Knösel, Thomas, Abdel-Rahman, Sultan, Schmidt, Michael, Hiddemann, Wolfgang, and Jauch, Karl-Walter
- Published
- 2018
- Full Text
- View/download PDF
12. Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements.
- Author
-
Trefná, Hana Dobšíček, Crezee, Hans, Schmidt, Manfred, Marder, Dietmar, Lamprecht, Ulf, Ehmann, Michael, Hartmann, Josefin, Nadobny, Jacek, Gellermann, Johanna, van Holthe, Netteke, Ghadjar, Pirus, Lomax, Nicoletta, Abdel-Rahman, Sultan, Bert, Christoph, Bakker, Akke, Hurwitz, Mark D., Diederich, Chris J., Stauffer, Paul R., and van Rhoon, Gerard C.
- Subjects
FEVER ,CLINICAL trials ,THERMOTHERAPY ,THERMOMETRY ,QUALITY assurance - Abstract
Quality assurance guidelines are essential to provide uniform execution of clinical trials and treatment in the application of hyperthermia. This document provides definitions for a good hyperthermia treatment and identifies the clinical conditions where a certain hyperthermia system can or cannot adequately heat the tumour volume. It also provides brief description of the characteristics and performance of the current electromagnetic (radiative and capacitive), ultrasound and infra-red heating techniques. This information helps to select the appropriate heating technique for the specific tumour location and size, and appropriate settings of the water bolus and thermometry. Finally, requirements of staff training and documentation are provided. The guidelines in this document focus on the clinical application and are complemented with a second, more technical quality assurance document providing instructions and procedure to determine essential parameters that describe heating properties of the applicator for superficial hyperthermia. Both sets of guidelines were developed by the ESHO Technical Committee with participation of senior STM members and members of the Atzelsberg Circle. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
13. CT fluoroscopy-guided closed-tip catheter placement before regional hyperthermia treatment of soft tissue sarcomas: 5-Year experience in 35 consecutive patients.
- Author
-
Strobl, Frederik F., Azam, Houman, Schwarz, Jens B., Paprottka, Philipp M., Geith, Tobias, Abdel-Rahman, Sultan, Zilles, Benjamin, Lindner, Lars H., Reiser, Maximilian F., and Trumm, Christoph G.
- Subjects
SARCOMA ,FLUOROSCOPY ,THERMOTHERAPY ,THERMOMETRY ,CANCER research - Abstract
Purpose: This study was designed to assess technical success and complications in patients with high-risk soft tissue sarcomas undergoing CT fluoroscopy-guided closed-tip catheter placement before treatment with combined chemotherapy and regional hyperthermia.Materials and methods: This retrospective study comprised all patients referred for insertion of closed-tip catheters for the introduction of thermometry probes before regional hyperthermia treatment at a single university centre from 2010 to 2015. Catheter placements were performed under local anaesthesia and intermittent CT fluoroscopy guidance. Technical success, complication rate, duration of catheter insertion and dose–length product (DLP) were analysed. Technical success was defined as intratumoural catheter placement suitable for subsequent thermometry.Results: A total of 35 procedures were performed on 35 patients (22 men, 13 women). In 34 out of 35 interventions catheters were inserted successfully; in one patient catheter placement was not feasible. No intra-interventional complications occurred. In six patients post-interventional complications were observed – two major (one abscess formation and one severe catheter dislocation) and four minor complications. Technical failure was observed in 11.4% of patients, especially catheter kinking. A total of 55 catheters were placed, with a mean number of 1.7 ± 0.7 per patient. Mean total DLP was 723.2 ± 355.9 mGy*cm.Conclusion: CT fluoroscopy-guided closed-tip catheter placement into high-risk soft tissue sarcomas was characterised by high technical success and relatively low complication rate. While major complications were rarely observed, catheter-kinking preventing successful thermometry represented the most frequent technical failure. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
14. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.
- Author
-
Tschoep-Lechner, Katharina Elisabeth, Milani, Valeria, Berger, Frank, Dieterle, Nelli, Abdel-Rahman, Sultan, Salat, Christoph, and Issels, Rolf-Dieter
- Subjects
CISPLATIN ,PANCREATIC cancer treatment ,DISEASE progression ,TOXICITY testing ,CANCER chemotherapy ,THERAPEUTICS ,THERMOTHERAPY - Abstract
Purpose: There is no standard second-line therapy for patients with advanced pancreatic cancer (APC) after gemcitabine (G) failure. Cisplatin (Cis)-based chemotherapy has shown activity in APC. It is proven that cytotoxicity of G and Cis is enhanced by heat exposure at 40° to 42°C. Therefore G plus Cis with regional hyperthermia (RHT) might be beneficial for patients with G-refractory APC. Patients and methods: We retrospectively analysed 23 patients with advanced ( n = 2) or metastatic ( n = 21) pancreatic cancer with relapse after G mono first-line chemotherapy ( n = 23). Patients had received G (day 1, 1000 mg/m
2 ) and Cis (day 2 and 4, 25 mg/m2 ) in combination with RHT (day 2 and 4, 1 h) biweekly for 4 months. We analysed feasibility, toxicity, time to second progression (TTP2), overall survival (OS) and clinical response. Results: Between October 1999 and August 2008 23 patients were treated. Haematological toxicity was low with no grade 4 event. Hyperthermia-associated toxicity consisted of discomfort because of bolus pressure (3%), power-related pain (7%) or position-related pain (17%). Median TTP1 was 5.9 months (95% confidence interval (CI): 2.6-9.2), median TTP2 was 4.3 months (95%CI: 1.2-7.4) and OS 12.9 months (95%CI: 9.9-15.9). The disease control rate in 16 patients with available CT scans was 50%. Conclusion: We show first clinical data of G plus Cis with RHT being clinically active in G-pretreated APC with low toxicity. A prospective controlled phase II second-line clinical trial (EudraCT: 2005-003855-11) and a randomised phase III adjuvant clinical trial offering this treatment (HEAT; EudraCT: 2008-004802-14) are currently open for recruitment. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
15. Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
- Author
-
Stahl, Robert, Wang, Tungte, Lindner, Lars H., Abdel-Rahman, Sultan, Santl, Margareta, Reiser, Maximilian F., and Issels, Rolf D.
- Subjects
DRUG therapy ,FEVER ,SOFT tissue tumors ,NECROSIS ,CLINICAL trials - Abstract
Purpose: To compare the radiological criteria RECIST, WHO, and tumor volume for evaluation of tumor response in patients with soft tissue sarcomas (STS) showing either good or poor pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia, and to examine the dependence of the findings on the applied thermal dose. Materials and methods:19 patients with pathohistological complete response (no vital tumor cells, group 1) and 27 with pathohistological no response (<25% necrosis, group 2) were selected from our previous clinical trials. The change in tumor size before and after therapy was determined. Intratumoral temperature (T90) and thermal dose (CEM 43°C T90) were calculated for 13 patients. Results: In the first group, 6 partial response (PR) and 13 stable disease (SD) according to RECIST, 7 PR and 12 SD according to WHO, 7 PR and 12 SD according to volumetric criteria were evaluated. In the second group, the results were 10 PR and 17 SD (RECIST), 9 PR and 18 SD (WHO), 8 PR and 19 SD (volume). The concordance of these criteria was 73.7% in group 1 and 74% in group 2. PR and SD were equally distributed in both groups (p > 0.421). Thermal parameters were not different between the groups (p > 0.327). Conclusions: SD or PR in radiological response assessment does not correlate with the pathohistological response after neoadjuvant thermochemotherapy. RECIST, WHO and volumetric criteria for response evaluation in STS are in substantial agreement. For irregularly shaped lesions, volumetric criteria seem to be more appropriate. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
16. Efficacy of Consolidation High-Dose Chemotherapy with Ifosfamide, Carboplatin and Etoposide (HD-ICE) Followed by Autologous Peripheral Blood Stem Cell Rescue in Chemosensitive Patients with Metastatic Soft Tissue Sarcomas.
- Author
-
Schlemmer, Marcus, Wendtner, Clemens-Martin, Falk, Martin, Abdel-Rahman, Sultan, Licht, Thomas, Baumert, Jens, Straka, Christian, Hentrich, Marcus, Salat, Christoph, Hiddemann, Wolfgang, and Issels, Rolf-Dieter
- Subjects
DRUG therapy ,CANCER prognosis ,DOXORUBICIN ,ETOPOSIDE ,DRUG side effects - Abstract
Background: Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy. We report phase II data of high-dose chemotherapy and peripheral blood stem cell (PBSC) rescue in patients with MSTS responding to AI-G chemotherapy. Patients and Methods: From 1997 to 2002, 55 patients with MSTS were prospectively treated with 4 cycles of AI-G (doxorubicin 75 mg/m
2 , ifosfamide 6 g/m2 with G-CSF support). Responders received 2 further cycles of AI-G with collection of PBSCs. High-dose chemotherapy consisted of ifosfamide 12 g/m2 , carboplatin 1.2 g/m2 and etoposide 1.2 g/m2 (HD-ICE) followed by reinfusion of PBSCs. Results: Twenty-one of 55 patients (38%) were assessed as responders (3 complete response, 18 partial response). All but 2 patients refusing treatment received high-dose chemotherapy with PBSC rescue leading to grade IV hematologic toxicity without severe infections in all patients. No toxic death occurred. After a median follow-up time of 30 months, the median progression-free time was 12 months and survival time was 22 months for the entire group. By intent-to-treat analysis the probability of 5-year progression-free survival was significantly higher for patients allocated to HD-ICE compared to patients receiving second-line chemotherapy after failure of AI-G (14 vs. 3%; p = 0.003). The estimated 5-year overall survival between the 2 groups was different (27% vs. not reached) but did not reach significance (p = 0.08). Conclusion: HD-ICE is feasible and promising in patients with chemosensitive MSTS. A randomized phase III trial is warranted to further define the role of HD-ICE as consolidation treatment in these patients. Copyright © 2006 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
17. Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer.
- Author
-
Ott, Oliver J., Gani, Cihan, Lindner, Lars H., Schmidt, Manfred, Lamprecht, Ulf, Abdel-Rahman, Sultan, Hinke, Axel, Weissmann, Thomas, Hartmann, Arndt, Issels, Rolf D., Zips, Daniel, Belka, Claus, Grützmann, Robert, Fietkau, Rainer, and Morganti, Alessio Giuseppe
- Subjects
THERMOTHERAPY ,RECTUM tumors ,CANCER relapse ,ADJUVANT treatment of cancer ,CHEMORADIOTHERAPY ,CANCER patients - Abstract
Simple Summary: The HyRec trial was initially designed to optimize and standardize the treatment of locally recurrent rectal cancer (LRRC). An escalated neoadjuvant treatment schedule, consisting of curative radiotherapy, concurrent chemotherapy with 5-Fluorouracil and Oxaliplatin, and additional regional hyperthermia, was evaluated with the intention to increase the rate of curative resections. Primary endpoints were the feasibility rate defined by the number of therapy-limiting toxicity or treatment withdrawal, and the pathologically confirmed complete remission (pCR) rate. Between 2012 and 2018, 111 patients with Union for International Cancer Control (UICC) stage IIB-IV or any locally recurrent rectal cancer were included. The intensified neoadjuvant and multimodality treatment schedule was feasible and led to comparable early toxicity rates as described by other trials that used the similar chemoradiation protocol. The presented treatment regimen resulted in a very high pCR rate and appears as a promising option for patients with LRRC. Background: To prospectively analyze feasibility and pathological complete response (pCR) rates of neoadjuvant chemoradiotherapy combined with regional hyperthermia (RHT) in patients with locally advanced (LARC) or recurrent (LRRC) rectal cancer. Methods: between 2012 and 2018, 111 patients with UICC stage IIB-IV or any locally recurrent rectal cancer were included (HyRec-Trial, ClinicalTrials.gov Identifier: NCT01716949). Patients received radiotherapy with concurrent 5-Fluororuracil (5-FU)/Capecitabine and Oxaliplatin, and RHT. Stage 1 feasibility analysis evaluated dose-limiting toxicities (DLT) after 19 patients, stage 2 after 59 evaluable patients. Analysis of the pCR rate was based on histopathological reports. Results: the feasibility rates for stages 1 and 2 were 90% (17/19) and 73% (43/59), respectively. In the intention-to-treat population the pCR rate was 19% (20/105; 90% confidence interval (CI) 13.0–26.5). In the per-protocol-analysis, complete tumor regression was seen in 28% (18/64) and 38% (3/8) of the patients with LARC and LRRC, respectively. Complete resection rates (R0) among patients with LARC and LRRC who received surgery were 99% (78/84) and 67% (8/12). Conclusions: the intensified neoadjuvant and multimodality treatment schedule was feasible and led to comparable early toxicity rates as described by other trials that used the similar chemoradiation protocol. The presented treatment regimen resulted in a very high pCR rate and appears as a promising option for patients with LRRC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Quality assurance guidelines for superficial hyperthermia clinical trials
- Author
-
Dobšíček Trefná, Hana, Crezee, Johannes, Schmidt, Manfred, Marder, Dietmar, Lamprecht, Ulf, Ehmann, Michael, Nadobny, Jacek, Hartmann, Josefin, Lomax, Nicolleta, Abdel-Rahman, Sultan, Curto, Sergio, Bakker, Akke, Hurwitz, Mark D., Diederich, Chris J., Stauffer, Paul R., Van Rhoon, Gerard C., and Radiotherapy
- Subjects
Applicator ,Phantome ,Qualitätssicherung ,Clinical Trials as Topic ,Internationality ,Wasserbolus ,Quality Assurance, Health Care ,Infrared Rays ,Review Article ,Equipment Design ,Hyperthermia, Induced ,Quality assurance ,Phantoms ,Equipment Failure Analysis ,Oncology ,Radiology Nuclear Medicine and imaging ,Germany ,Practice Guidelines as Topic ,Hyperthermie, lokale ,Applikator ,Hyperthermia, superficial ,Microwaves ,Water bolus ,Heating criteria ,Heizkriterien - Abstract
Quality assurance (QA) guidelines are essential to provide uniform execution of clinical trials with uniform quality hyperthermia treatments. This document outlines the requirements for appropriate QA of all current superficial heating equipment including electromagnetic (radiative and capacitive), ultrasound, and infrared heating techniques. Detailed instructions are provided how to characterize and document the performance of these hyperthermia applicators in order to apply reproducible hyperthermia treatments of uniform high quality. Earlier documents used specific absorption rate (SAR) to define and characterize applicator performance. In these QA guidelines, temperature rise is the leading parameter for characterization of applicator performance. The intention of this approach is that characterization can be achieved with affordable equipment and easy-to-implement procedures. These characteristics are essential to establish for each individual applicator the specific maximum size and depth of tumors that can be heated adequately. The guidelines in this document are supplemented with a second set of guidelines focusing on the clinical application. Both sets of guidelines were developed by the European Society for Hyperthermic Oncology (ESHO) Technical Committee with participation of senior Society of Thermal Medicine (STM) members and members of the Atzelsberg Circle.
- Full Text
- View/download PDF
19. Leitlinien zur Qualitätssicherung der lokalen Hyperthermie in klinischen Studien : II. Technische Anforderungen an Heizgeräte.
- Author
-
Dobšíček Trefná, Hana, Crezee, Johannes, Schmidt, Manfred, Marder, Dietmar, Lamprecht, Ulf, Ehmann, Michael, Nadobny, Jacek, Hartmann, Josefin, Lomax, Nicolleta, Abdel-Rahman, Sultan, Curto, Sergio, Bakker, Akke, Hurwitz, Mark D, Diederich, Chris J, Stauffer, Paul R, and Van Rhoon, Gerard C
- Subjects
QUALITY assurance standards ,CLINICAL trials ,INTERNATIONAL relations ,NONIONIZING radiation ,MEDICAL protocols ,MICROWAVES ,PRODUCT design ,THERMOTHERAPY ,MEDICAL equipment reliability ,EQUIPMENT & supplies - Abstract
Quality assurance (QA) guidelines are essential to provide uniform execution of clinical trials with uniform quality hyperthermia treatments. This document outlines the requirements for appropriate QA of all current superficial heating equipment including electromagnetic (radiative and capacitive), ultrasound, and infrared heating techniques. Detailed instructions are provided how to characterize and document the performance of these hyperthermia applicators in order to apply reproducible hyperthermia treatments of uniform high quality. Earlier documents used specific absorption rate (SAR) to define and characterize applicator performance. In these QA guidelines, temperature rise is the leading parameter for characterization of applicator performance. The intention of this approach is that characterization can be achieved with affordable equipment and easy-to-implement procedures. These characteristics are essential to establish for each individual applicator the specific maximum size and depth of tumors that can be heated adequately. The guidelines in this document are supplemented with a second set of guidelines focusing on the clinical application. Both sets of guidelines were developed by the European Society for Hyperthermic Oncology (ESHO) Technical Committee with participation of senior Society of Thermal Medicine (STM) members and members of the Atzelsberg Circle. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial.
- Author
-
Issels, Rolf D., Noessner, Elfriede, Lindner, Lars H., Schmidt, Michael, Albertsmeier, Markus, Blay, Jean-Yves, Stutz, Emanuel, Xu, Yujun, Buecklein, Veit, Altendorf-Hofmann, Annelore, Abdel-Rahman, Sultan, Mansmann, Ulrich, von Bergwelt-Baildon, Michael, and Knoesel, Thomas
- Subjects
- *
PREOPERATIVE care , *BODY temperature , *BIOPSY , *CONFIDENCE intervals , *CANCER chemotherapy , *MULTIVARIATE analysis , *SOFT tissue tumors , *RANDOMIZED controlled trials , *LYMPHOCYTES , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *TUMOR markers , *SARCOMA - Abstract
The EORTC 62961-ESHO 95 randomised trial showed improved long-term survival of patients with high-risk soft-tissue sarcoma by adding regional hyperthermia to neoadjuvant chemotherapy. We hypothesised that immune infiltrate of patients treated with neoadjuvant therapy associate with clinical outcome. Tumour infiltrating lymphocytes (TILs) and CD8, FOXP3, PD-1, and PD-L1 were evaluated in sequential biopsies of patients after four cycles of therapy. From a subgroup of 109 patients who had been randomised between July 1997 and November 2006 to neoadjuvant chemotherapy (53 patients) or neoadjuvant chemotherapy with regional hyperthermia (56 patients), 137 biopsies were obtained. TILs increased in paired second biopsies independent of treatment allocation (p < 0.001). FOXP3 regulatory T cells decreased (p = 0.002), and PD-L1 expression of tumours became undetectable. In the multivariate analysis, post-treatment high TILs correlated to LPFS (HR: 0.34; 95% CI 0.15–0.75; p = 0.008) and DFS (HR: 0.38; 95% CI 0.17–0.82; p = 0.015). In comparing post-treatment immune infiltrate between treatment arms, tumour response was associated with neoadjuvant chemotherapy with regional hyperthermia (p = 0.013) and high TILs (p = 0.064). High CD8 cell infiltration was associated with improved LPFS (HR: 0.27; 95% CI 0.09–0.79; Log-rank p = 0.011) and DFS (HR: 0.25; 95% CI 0.09–0.73; Log-rank p = 0.006). Improved survival at 10 years was associated with immune infiltrate after neoadjuvant chemotherapy with regional hyperthermia. Preoperative therapy re-programs a non-inflamed tumour at baseline into an inflamed tumour. The post-treatment immune infiltrate became predictive for clinical outcomes. The combination with regional hyperthermia primes the tumour microenvironment, enabling enhanced anti-tumour immune activity in high-risk soft tissue sarcomas. ClinicalTrials.gov, NCT00003052. • Preoperative therapy turned the non-inflamed tumour into an immune infiltrated tumour. • Immune infiltrate associated with response and survival when hyperthermia was added. • Neoadjuvant chemotherapy with hyperthermia primed an anti-tumour microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Regional hyperthermia for soft tissue sarcoma - a survey on current practice, controversies and consensus among 12 European centers.
- Author
-
Roohani S, Ehret F, Beck M, Veltsista DP, Nadobny J, Zschaeck S, Abdel-Rahman S, Eckert F, Flörcken A, Issels RD, Klöck S, Krempien R, Lindner LH, Notter M, Ott OJ, Pink D, Potkrajcic V, Reichardt P, Riesterer O, Spałek MJ, Stutz E, Wessalowski R, Zilli T, Zips D, Ghadjar P, and Kaul D
- Subjects
- Humans, Europe, Surveys and Questionnaires, Cross-Sectional Studies, Consensus, Sarcoma therapy, Hyperthermia, Induced methods
- Abstract
Purpose: To analyze the current practice of regional hyperthermia (RHT) for soft tissue sarcoma (STS) at 12 European centers to provide an overview, find consensuses and identify controversies necessary for future guidelines and clinical trials., Methods: In this cross-sectional survey study, a 27-item questionnaire assessing clinical subjects and procedural details on RHT for STS was distributed to 12 European cancer centers for RHT., Results: We have identified seven controversies and five consensus points. Of 12 centers, 6 offer both, RHT with chemotherapy (CTX) or with radiotherapy (RT). Two centers only offer RHT with CTX and four centers only offer RHT with RT. All 12 centers apply RHT for localized, high-risk STS of the extremities, trunk wall and retroperitoneum. However, eight centers also use RHT in metastatic STS, five in palliative STS, eight for superficial STS and six for low-grade STS. Pretherapeutic imaging for RHT treatment planning is used by 10 centers, 9 centers set 40-43 °C as the intratumoral target temperature, and all centers use skin detectors or probes in body orifices for thermometry., Discussion: There is disagreement regarding the integration of RHT in contemporary interdisciplinary care of STS patients. Many clinical controversies exist that require a standardized consensus guideline and innovative study ideas. At the same time, our data has shown that existing guidelines and decades of experience with the technique of RHT have mostly standardized procedural aspects., Conclusions: The provided results may serve as a basis for future guidelines and inform future clinical trials for RHT in STS patients.
- Published
- 2024
- Full Text
- View/download PDF
22. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study.
- Author
-
Angele MK, Albertsmeier M, Prix NJ, Hohenberger P, Abdel-Rahman S, Dieterle N, Schmidt M, Mansmann U, Bruns CJ, Issels RD, Jauch KW, and Lindner LH
- Subjects
- Abdomen, Adolescent, Adult, Aged, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hyperthermia, Induced methods, Retroperitoneal Neoplasms therapy, Sarcoma therapy
- Abstract
Objective: To determine whether regional hyperthermia (RHT) in addition to chemotherapy improves local tumor control after macroscopically complete resection of abdominal or retroperitoneal high-risk sarcomas., Background: Within the prospectively randomized EORTC 62961 phase-III trial, RHT and systemic chemotherapy significantly improved local progression-free survival (LPFS) and disease-free survival (DFS) in patients with abdominal and extremity sarcomas. That trial included macroscopically complete and R2 resections., Methods: A subgroup analysis of the EORTC trial was performed and long-term survival determined. From 341 patients, 149 (median age 52 years, 18-69) were identified with macroscopic complete resection (R0, R1) of abdominal and retroperitoneal soft-tissue sarcomas (median diameter 10 cm, G2 48.3%, G3 51.7%). Seventy-six patients were treated with EIA (etoposide, ifosfamide, doxorubicin)+RHT (≥5 cycles: 69.7%) versus 73 patients receiving EIA alone (≥5 cycles: 52.1%, P=0.027). LPFS and DFS as well as overall survival were determined., Results: RHT and systemic chemotherapy significantly improved LPFS (56% vs 45% after 5 years, P=0.044) and DFS (34% vs 27% after 5 years, P=0.040). Overall survival was not significantly improved in the RHT group (57% vs 55% after 5 years, P=0.82). Perioperative morbidity and mortality were not significantly different between groups., Conclusions: In patients with macroscopically complete tumor resection, RHT in addition to chemotherapy resulted in significantly improved local tumor control and DFS without increasing surgical complications. Within a multimodal therapeutic concept for abdominal and retroperitoneal high-risk sarcomas, RHT is a treatment option beside radical surgery and should be further evaluated in future trials.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.